Using data from the ongoing P1093 and the ODYSSEY (PENTA20) study, ViiV Healthcare has filed submissions to the FDA and EMA for the first-ever dispersible formulation of dolutegravir (DTG) for children living with HIV. If approved, this new formulation of dolutegravir...
Data from ODYSSEY are used by ViiV Healthcare to file FDA and EMA submissions for the first-ever dispersible formulation of dolutegravir for children living with HIV
read more